PDF herunterladen
Semin Reprod Med 2019; 37(05/06): 265-272
DOI: 10.1055/s-0039-1700531
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Progesterone Elevation and Preventive Strategies to Avoid Implantation Failure

Gurkan Bozdag
1   Department of Obstetrics and Gynecology, School of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey
,
Esengul Turkyilmaz
2   Department of Obstetrics and Gynecology, Ankara Bilkent City Hospital, Ankara, Turkey
,
Sule Yildiz
3   Department of Obstetrics and Gynecology, School of Medicine, Koc University, Istanbul, Turkey
,
Sezcan Mumusoglu
1   Department of Obstetrics and Gynecology, School of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey
,
Hakan Yarali
1   Department of Obstetrics and Gynecology, School of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey
4   Anatolia IVF and Women Health Centre, Ankara, Turkey
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. Januar 2020 (online)

    Lizenzen und Reprints

Abstract

Despite the wide utilization of gonadotropin-releasing hormone analogs, progesterone elevation (P4E) in the late follicular phase occurs in 5 to 30% of all ovarian stimulation (OS) cycles. Although the detrimental effect of P4E on pregnancy rates in fresh in vitro fertilization cycles is valid in all subsets of cases, higher levels of P4 and a longer duration of P4E may be needed in patients with a hyper-ovarian response in order for a negative impact on pregnancy rates to occur. Available preclinical and clinical data suggest that aggressive OS with high doses of follicle-stimulating hormone might increase 3β-hydroxy steroid dehydrogenase and 17β-hydroxy steroid dehydrogenase enzyme activity in human granulosa cells, which leads to high P4 production and hence a higher amount of leakage to the systemic circulation due to a lack of 17α-hydroxylase enzyme expression in human species. High P4 concentrations appear to alter gene expression in the endometrium; however, caution is necessary regarding its potential effect on oocyte/embryo quality with respect to the role of inherent follicular disruption in some women. In terms of the mechanism of overproduction in P4 synthesis, the main preventive strategy should be avoiding aggressive stimulation. Unfortunately, there is lack of large-scale randomized controlled trials for other approaches, including deferred embryo transfer in the thaw cycle. Since there is a significant inter-assay variability for P4 measurement, it may be wise to recommend that every center should define their own P4E and the level needed for harm to occur based on their own assays and datasets before deciding the best approach.

Keywords

progesterone elevation - in vitro fertilization - ovarian stimulation - threshold - frozen embryo transfer
 

  • References

  • 1 Schoolcraft W, Sinton E, Schlenker T, Huynh D, Hamilton F, Meldrum DR. Lower pregnancy rate with premature luteinization during pituitary suppression with leuprolide acetate. Fertil Steril 1991; 55 (03) 563-566
    CrossrefPubMedGoogle Scholar
  • 2 Felberbaum R, Diedrich K. Ovarian stimulation for in-vitro fertilization/intracytoplasmic sperm injection with gonadotrophins and gonadotrophin-releasing hormone analogues: agonists and antagonists. Hum Reprod 1999; 14 (Suppl. 01) 207-221
    CrossrefPubMedGoogle Scholar
  • 3 Bosch E, Valencia I, Escudero E. , et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 2003; 80 (06) 1444-1449
    CrossrefPubMedGoogle Scholar
  • 4 Ubaldi F, Albano C, Peukert M. , et al. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles. Hum Reprod 1996; 11 (07) 1405-1407
    CrossrefPubMedGoogle Scholar
  • 5 Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update 2013; 19 (05) 433-457
    CrossrefPubMedGoogle Scholar
  • 6 Patton PE, Lim JY, Hickok LR, Kettel LM, Larson JM, Pau KY. Precision of progesterone measurements with the use of automated immunoassay analyzers and the impact on clinical decisions for in vitro fertilization. Fertil Steril 2014; 101 (06) 1629-1636
    CrossrefPubMedGoogle Scholar
  • 7 Thomsen LH, Kesmodel US, Andersen CY, Humaidan P. Daytime variation in serum progesterone during the mid-luteal phase in women undergoing in vitro fertilization treatment. Front Endocrinol (Lausanne) 2018; 9: 92
    CrossrefPubMedGoogle Scholar
  • 8 Venetis CA, Kolibianakis EM, Papanikolaou E, Bontis J, Devroey P, Tarlatzis BC. Is progesterone elevation on the day of human chorionic gonadotrophin administration associated with the probability of pregnancy in in vitro fertilization? A systematic review and meta-analysis. Hum Reprod Update 2007; 13 (04) 343-355
    CrossrefPubMedGoogle Scholar
  • 9 Kyrou D, Kolibianakis EM, Fatemi HM. , et al. High exposure to progesterone between the end of menstruation and the day of triggering final oocyte maturation is associated with a decreased probability of pregnancy in patients treated by in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2011; 96 (04) 884-888
    CrossrefPubMedGoogle Scholar
  • 10 Huang CC, Lien YR, Chen HF. , et al. The duration of pre-ovulatory serum progesterone elevation before hCG administration affects the outcome of IVF/ICSI cycles. Hum Reprod 2012; 27 (07) 2036-2045
    CrossrefPubMedGoogle Scholar
  • 11 Bosch E, Labarta E, Crespo J. , et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod 2010; 25 (08) 2092-2100
    CrossrefPubMedGoogle Scholar
  • 12 Griesinger G, Mannaerts B, Andersen CY, Witjes H, Kolibianakis EM, Gordon K. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertil Steril 2013; 100 (06) 1622-8.e1 , 3
    CrossrefPubMedGoogle Scholar
  • 13 Xu B, Li Z, Zhang H. , et al. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: an analysis of more than 10,000 cycles. Fertil Steril 2012; 97 (06) 1321-7.e1 , 4
    CrossrefPubMedGoogle Scholar
  • 14 Venetis CA, Kolibianakis EM, Bosdou JK. , et al. Estimating the net effect of progesterone elevation on the day of hCG on live birth rates after IVF: a cohort analysis of 3296 IVF cycles. Hum Reprod 2015; 30 (03) 684-691
    CrossrefPubMedGoogle Scholar
  • 15 De Geyter C, De Geyter M, Huber PR, Nieschlag E, Holzgreve W. Progesterone serum levels during the follicular phase of the menstrual cycle originate from the crosstalk between the ovaries and the adrenal cortex. Hum Reprod 2002; 17 (04) 933-939
    CrossrefPubMedGoogle Scholar
  • 16 Liu S, Shi L, Wang T, Shi J. Effect of low-dose dexamethasone on patients with elevated early follicular phase progesterone level and pregnancy outcomes in IVF-ET treatment: a randomized controlled clinical trial. Clin Endocrinol (Oxf) 2018; 89 (06) 771-778
    CrossrefPubMedGoogle Scholar
  • 17 Papaleo E, Corti L, Vanni VS. , et al. Basal progesterone level as the main determinant of progesterone elevation on the day of hCG triggering in controlled ovarian stimulation cycles. Arch Gynecol Obstet 2014; 290 (01) 169-176
    PubMedGoogle Scholar
  • 18 Oktem O, Akin N, Bildik G. , et al. FSH Stimulation promotes progesterone synthesis and output from human granulosa cells without luteinization. Hum Reprod 2017; 32 (03) 643-652
    CrossrefPubMedGoogle Scholar
  • 19 Oren I, Fleishman SJ, Kessel A, Ben-Tal N. Free diffusion of steroid hormones across biomembranes: a simplex search with implicit solvent model calculations. Biophys J 2004; 87 (02) 768-779
    CrossrefPubMedGoogle Scholar
  • 20 Gorodeski GI. Estrogen increases the permeability of the cultured human cervical epithelium by modulating cell deformability. Am J Physiol 1998; 275 (03) C888-C899
    CrossrefPubMedGoogle Scholar
  • 21 Werner MD, Forman EJ, Hong KH, Franasiak JM, Molinaro TA, Scott Jr RT. Defining the “sweet spot” for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in vitro fertilization cycles. Fertil Steril 2014; 102 (05) 1312-1317
    CrossrefPubMedGoogle Scholar
  • 22 Younis JS, Matilsky M, Radin O, Ben-Ami M. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist. Fertil Steril 2001; 76 (02) 294-299
    CrossrefPubMedGoogle Scholar
  • 23 Shufaro Y, Sapir O, Oron G. , et al. Progesterone-to-follicle index is better correlated with in vitro fertilization cycle outcome than blood progesterone level. Fertil Steril 2015; 103 (03) 669-74.e3
    CrossrefPubMedGoogle Scholar
  • 24 Roque M, Valle M, Sampaio M, Geber S, Checa MA. Ratio of progesterone-to-number of follicles as a prognostic tool for in vitro fertilization cycles. J Assist Reprod Genet 2015; 32 (06) 951-957
    CrossrefPubMedGoogle Scholar
  • 25 Aflatoonian A, Davar R, Hojjat F. Elevated serum progesterone/ MII oocyte ratio on the day of human chorionic gonadotropin administration can predict impaired endometrial receptivity. Iran J Reprod Med 2014; 12 (06) 427-434
    PubMedGoogle Scholar
  • 26 Hill MJ, Healy MW, Richter KS. , et al. Revisiting the progesterone to oocyte ratio. Fertil Steril 2017; 107 (03) 671-676.e2
    CrossrefPubMedGoogle Scholar
  • 27 Younis JS. The role of progesterone/estradiol ratio in exploring the mechanism of late follicular progesterone elevation in low ovarian reserve women. Med Hypotheses 2019; 125: 126-128
    CrossrefPubMedGoogle Scholar
  • 28 Van Vaerenbergh I, Fatemi HM, Blockeel C. , et al. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online 2011; 22 (03) 263-271
    CrossrefPubMedGoogle Scholar
  • 29 Labarta E, Martínez-Conejero JA, Alamá P. , et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod 2011; 26 (07) 1813-1825
    CrossrefPubMedGoogle Scholar
  • 30 Melo MA, Meseguer M, Garrido N, Bosch E, Pellicer A, Remohí J. The significance of premature luteinization in an oocyte-donation programme. Hum Reprod 2006; 21 (06) 1503-1507
    CrossrefPubMedGoogle Scholar
  • 31 Racca A, Santos-Ribeiro S, De Munck N. , et al. Impact of late-follicular phase elevated serum progesterone on cumulative live birth rates: is there a deleterious effect on embryo quality?. Hum Reprod 2018; 33 (05) 860-868
    CrossrefPubMedGoogle Scholar
  • 32 Vanni VS, Somigliana E, Reschini M. , et al. Top-quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF/ICSI cycles. PLoS One 2017; 12 (05) e0176482
    CrossrefPubMedGoogle Scholar
  • 33 Kuang Y, Hong Q, Chen Q. , et al. Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril 2014; 101 (01) 105-111
    CrossrefPubMedGoogle Scholar
  • 34 Kuang Y, Chen Q, Fu Y. , et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 2015; 104 (01) 62-70.e3
    CrossrefPubMedGoogle Scholar
  • 35 Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006; 21 (12) 3217-3227
    CrossrefPubMedGoogle Scholar
  • 36 Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. ; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril 2012; 97 (03) 561-571
    CrossrefPubMedGoogle Scholar
  • 37 Lawrenz B, Beligotti F, Engelmann N, Gates D, Fatemi HM. Impact of gonadotropin type on progesterone elevation during ovarian stimulation in GnRH antagonist cycles. Hum Reprod 2016; 31 (11) 2554-2560
    CrossrefPubMedGoogle Scholar
  • 38 Wang A, Santistevan A, Hunter Cohn K. , et al. Freeze-only versus fresh embryo transfer in a multicenter matched cohort study: contribution of progesterone and maternal age to success rates. Fertil Steril 2017; 108 (02) 254-261.e4
    CrossrefPubMedGoogle Scholar
  • 39 Healy MW, Patounakis G, Connell MT. , et al. Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles?. Fertil Steril 2016; 105 (01) 93-9.e1
    CrossrefPubMedGoogle Scholar
  • 40 Yang S, Pang T, Li R. , et al. The individualized choice of embryo transfer timing for patients with elevated serum progesterone level on the HCG day in IVF/ICSI cycles: a prospective randomized clinical study. Gynecol Endocrinol 2015; 31 (05) 355-358
    CrossrefPubMedGoogle Scholar
  • 41 Papanikolaou EG, Kolibianakis EM, Pozzobon C. , et al. Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertil Steril 2009; 91 (03) 949-952
    CrossrefPubMedGoogle Scholar
  • 42 Corti L, Papaleo E, Pagliardini L. , et al. Fresh blastocyst transfer as a clinical approach to overcome the detrimental effect of progesterone elevation at hCG triggering: a strategy in the context of the Italian law. Eur J Obstet Gynecol Reprod Biol 2013; 171 (01) 73-77
    CrossrefPubMedGoogle Scholar
  • 43 Healy MW, Yamasaki M, Patounakis G. , et al. The slow growing embryo and premature progesterone elevation: compounding factors for embryo-endometrial asynchrony. Hum Reprod 2017; 32 (02) 362-367
    CrossrefPubMedGoogle Scholar
  • 44 Huang Y, Wang EY, Du QY. , et al. Progesterone elevation on the day of human chorionic gonadotropin administration adversely affects the outcome of IVF with transferred embryos at different developmental stages. Reprod Biol Endocrinol 2015; 13: 82
    CrossrefPubMedGoogle Scholar
  • 45 Ochsenkühn R, Arzberger A, von Schönfeldt V. , et al. Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted reproductive technology: a retrospective study with 2,555 fresh embryo transfers. Fertil Steril 2012; 98 (02) 347-354
    CrossrefPubMedGoogle Scholar
  • 46 Hill MJ, Healy MW, Richter KS. , et al. Defining thresholds for abnormal premature progesterone levels during ovarian stimulation for assisted reproduction technologies. Fertil Steril 2018; 110 (04) 671-679.e2
    CrossrefPubMedGoogle Scholar
  • 47 Esteves SC, Khastgir G, Shah J. , et al. Association between progesterone elevation on the day of human chronic gonadotropin trigger and pregnancy outcomes after fresh embryo transfer in in vitro fertilization/intracytoplasmic sperm injection cycles. Front Endocrinol (Lausanne) 2018; 9: 201
    CrossrefPubMedGoogle Scholar